<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151371</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0917</org_study_id>
    <nct_id>NCT01151371</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the clinical performance of silicone hydrogel daily
      disposable contact lenses, conventional hydrogel daily disposable contact lenses and silicone
      hydrogel monthly replacement contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2010</start_date>
  <completion_date type="Actual">April 1, 2010</completion_date>
  <primary_completion_date type="Actual">April 1, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Comfort Narafilcon B v. Nelfilcon A</measure>
    <time_frame>After 1 week</time_frame>
    <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A</measure>
    <time_frame>After 1 Week</time_frame>
    <description>Redness scale of 0 to 4, where 0=None, 4=Severe redness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B</measure>
    <time_frame>After 4 Weeks</time_frame>
    <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B</measure>
    <time_frame>After 4 Weeks</time_frame>
    <description>Redness scale of 0 to 4, where 0=None, and 4=Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A</measure>
    <time_frame>After 1 Week</time_frame>
    <description>Standard scale of 0 to 3 where 0=None, 3=Severe staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A</measure>
    <time_frame>After 1 Week</time_frame>
    <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A</measure>
    <time_frame>After 1 Week</time_frame>
    <description>Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A</measure>
    <time_frame>After 1 Week</time_frame>
    <description>Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B</measure>
    <time_frame>After 4 Weeks</time_frame>
    <description>Scale of 0 to 3, where 0=none and 3=severe staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B</measure>
    <time_frame>After 4 Weeks</time_frame>
    <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B</measure>
    <time_frame>After 4 Weeks</time_frame>
    <description>Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B</measure>
    <time_frame>After 4 Weeks</time_frame>
    <description>Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">452</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>narafilcon B daily disposable 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nelfilcon A daily disponsable 1 week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lotrafilcon B daily wear, monthly replacement, 4-weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>narafilcon B contact lens</intervention_name>
    <description>Silicone Hydrogel Daily Disposable Contact Lenses</description>
    <arm_group_label>narafilcon B daily disposable 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nelfilcon A contact lens</intervention_name>
    <description>Conventional Hydrogel Daily Disposable Contact Lenses</description>
    <arm_group_label>nelfilcon A daily disponsable 1 week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lotrafilcon B contact lens</intervention_name>
    <description>Silicone Hydrogel Monthly Replacement Contact Lenses</description>
    <arm_group_label>lotrafilcon B daily wear, monthly replacement, 4-weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be no less than 18 and no more than 39 years of age.

          -  Sign Written Informed Consent and investigator to record this on Case Report Form (See
             separate document).

          -  Be willing and able to adhere to the instructions set out in the protocol.

          -  Own a cell phone and be willing to receive text messages during the day.

          -  Be an existing successful daily wear soft contact lens. For the purposes of this study
             this means wearing lenses for at least 6 hours per day, 5 days per week for the last
             month.

          -  No extended wear in the last 3 months.

          -  Subjective refraction must result in a vertexed spherical contact lens prescription
             between -1.00 and -6.00D.

          -  Have refractive astigmatism less than or equal to 1.00D in both eyes.

          -  Achieve visual acuity of 6/9 (20/30) or better in each eye.

          -  Require a visual correction in both eyes (no monofit or monovision allowed).

          -  Does not require presbyopic correction (i.e. Not using any presbyopic correction and
             measured add power of less than +1.00D).

          -  Have normal eyes with no evidence of abnormality or disease. For the purposes of this
             study a normal eye is defined as one having:

          -  No amblyopia.

          -  No evidence of lid abnormality or infection (including blepharitis/meibomitis).

               -  No conjunctival abnormality or infection.

               -  No clinically significant slit lamp findings (i.e. stromal edema,
                  vascularization, infiltrates or abnormal opacities).

               -  No other active ocular disease.

        Exclusion Criteria:

          -  Requires concurrent ocular medication.

          -  Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularization,
             tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of
             the cornea that would contraindicate contact lens wear.

          -  Clinically significant corneal staining (Grade 3 in more than one corneal region per
             eye).

          -  Requires presbyopic correction (i.e. Not using any presbyopic correction and measured
             add power of less than +1.00D).

          -  Has had refractive surgery.

          -  Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this
             study.

          -  Abnormal lacrimal secretions.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Keratoconus or other corneal irregularity.

          -  PMMA(polymethyl methacrylate), hybrid or RGP(rigid gas permeable) lens wear in the
             previous 8 weeks.

        Does not require presbyopic correction (i.e. Not using any presbyopic correction and
        measured add power of less than +1.00D).

          -  Any systemic illness which would contraindicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  Diabetic.

          -  Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease
             (e.g., HIV (Human immunodeficiency virus)).

          -  History of chronic eye disease (e.g. glaucoma or ARMD (age related macular
             degeneration)).

          -  Pregnancy, lactating or planning a pregnancy at the time of enrolment.

          -  Participation in any concurrent clinical trial or in last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Brea</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corona</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blue Springs</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Ozark</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chagrin Falls</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Olmsted</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <results_first_submitted>September 15, 2011</results_first_submitted>
  <results_first_submitted_qc>November 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2011</results_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Narafilcon B 4 Weeks</title>
          <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Nelfilcon A 1 Week</title>
          <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
        </group>
        <group group_id="P3">
          <title>Lotrafilcon B 4 Weeks</title>
          <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Narafilcon B 4 Weeks</title>
          <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Nelfilcon A 1 Week</title>
          <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
        </group>
        <group group_id="B3">
          <title>Lotrafilcon B 4 Weeks</title>
          <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="6.4"/>
                    <measurement group_id="B2" value="27.6" spread="6.0"/>
                    <measurement group_id="B3" value="28" spread="6.2"/>
                    <measurement group_id="B4" value="27.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="328"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort Narafilcon B v. Nelfilcon A</title>
        <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
        <time_frame>After 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort Narafilcon B v. Nelfilcon A</title>
          <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.32" spread="22.82" lower_limit="8.4" upper_limit="21.0"/>
                    <measurement group_id="O2" value="53.75" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A</title>
        <description>Redness scale of 0 to 4, where 0=None, 4=Severe redness</description>
        <time_frame>After 1 Week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A</title>
          <description>Redness scale of 0 to 4, where 0=None, 4=Severe redness</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.50"/>
                    <measurement group_id="O2" value="0.61" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B</title>
        <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
        <time_frame>After 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon B</title>
            <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B</title>
          <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.43" spread="23.37"/>
                    <measurement group_id="O2" value="53.91" spread="23.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A</title>
        <description>Standard scale of 0 to 3 where 0=None, 3=Severe staining</description>
        <time_frame>After 1 Week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A</title>
          <description>Standard scale of 0 to 3 where 0=None, 3=Severe staining</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.36"/>
                    <measurement group_id="O2" value="0.31" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A</title>
        <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
        <time_frame>After 1 Week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A</title>
          <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.05" spread="22.35"/>
                    <measurement group_id="O2" value="60.76" spread="22.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A</title>
        <description>Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort</description>
        <time_frame>After 1 Week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A</title>
          <description>Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.11"/>
                    <measurement group_id="O2" value="2.81" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A</title>
        <description>Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort.</description>
        <time_frame>After 1 Week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A</title>
          <description>Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="0.13"/>
                    <measurement group_id="O2" value="3.92" spread="010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B</title>
        <description>Scale of 0 to 3, where 0=none and 3=severe staining.</description>
        <time_frame>After 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon B</title>
            <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B</title>
          <description>Scale of 0 to 3, where 0=none and 3=severe staining.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.41"/>
                    <measurement group_id="O2" value="0.34" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B</title>
        <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
        <time_frame>After 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon B</title>
            <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B</title>
          <description>Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.58" spread="22.79"/>
                    <measurement group_id="O2" value="55.50" spread="22.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B</title>
        <description>Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort</description>
        <time_frame>After 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon B</title>
            <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B</title>
          <description>Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="0.11"/>
                    <measurement group_id="O2" value="2.95" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B</title>
        <description>Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort.</description>
        <time_frame>After 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon B</title>
            <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B</title>
          <description>Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="0.10"/>
                    <measurement group_id="O2" value="3.79" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B</title>
        <description>Redness scale of 0 to 4, where 0=None, and 4=Severe.</description>
        <time_frame>After 4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narafilcon B</title>
            <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon B</title>
            <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B</title>
          <description>Redness scale of 0 to 4, where 0=None, and 4=Severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.47"/>
                    <measurement group_id="O2" value="0.68" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Narafilcon B 4 Weeks</title>
          <description>lenses worn daily on a daily disposable/replacement schedule, for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Nelfilcon A 1 Week</title>
          <description>lenses worn daily on a daily disposable/replacement schedule, for 1 week</description>
        </group>
        <group group_id="E3">
          <title>Lotrafilcon B 4 Weeks</title>
          <description>lenses worn daily on a 1-month replacement schedule, for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must provide written approval for any publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathy Lorenz-Osborn, OD</name_or_title>
      <organization>Vistakon</organization>
      <phone>+1 904 443-1032</phone>
      <email>kosborn@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

